Pharmaceutical companies continue to battle to find an effective treatment for non-alcoholic steatohepatitis (NASH), an obesity-related form of
According to Bloomberg, Madrigal is expected to report results from a mid-stage NASH study sometime in the second half of 2018. The study is testing an experimental NASH therapy known as MGL-3196. Preliminary results published in December 2017 seemed promising, with MRI studies showing a decrease in liver fat at the three-month mark. Now, investors and researchers await biopsy results from patients treated with the therapy over eight months.
If successful, analysts say, the small pharmaceutical firm could get snapped up by one of its larger competitors, such as Gilead Sciences. Currently, Intercept is considered to be in the lead in the fatty liver disease treatment market with its drug
Potential investors are looking for a two-point change in what is known as
Analysts estimate that at this point Madrigal’s fatty liver disease drug has about a one in two chance of resulting in a major change in fibrosis. If successful, the treatment could cause Intercept shares to drop 5 percent and give hope to the millions of yet-untreated individuals living with
Comments
Comments